Sugi Predict

Sugi Predict / Compounds / SCHEMBL930683

SCHEMBL930683

SCHEMBL930683

CC(Cl)c1ccc(F)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 2/20 0.42
▸ TDO2 P48775 2/20 0.42
▸ ACHE P22303 1/20 0.41
▸ ADRB2 P07550 1/20 0.40
▸ AOC3 Q16853 2/20 0.38
▸ DAO P14920 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ HDAC3 O15379 1/20 0.37
▸ HDAC4 P56524 1/20 0.37
▸ HDAC1 Q13547 1/20 0.37
▸ HDAC7 Q8WUI4 1/20 0.37
▸ HDAC2 Q92769 1/20 0.37
▸ HDAC10 Q969S8 1/20 0.37
▸ HDAC11 Q96DB2 1/20 0.37
▸ HDAC8 Q9BY41 1/20 0.37
▸ HDAC6 Q9UBN7 1/20 0.37
▸ HDAC9 Q9UKV0 1/20 0.37
▸ HDAC5 Q9UQL6 1/20 0.37
▸ CYP17A1 P05093 1/20 0.36
▸ CHRM1 P11229 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11622289 0.93 CYP17A1 (0.44) IDO1TDO2ACHEADRB2AOC3
SCHEMBL2865480 0.85 ADRB2 (0.41) ADRB2HTTTRPA1ALDH1A1
SCHEMBL31489726 0.79 AOC3 (0.39) IDO1TDO2ACHEADRB2AOC3
SCHEMBL1046731 0.78 IDO1 (0.42) IDO1TDO2ACHEAOC3DAO
SCHEMBL7893366 0.77 ESR1 (0.52) IDO1TDO2ACHEAOC3DAO
SCHEMBL84956 0.77 IDO1 (0.46) IDO1TDO2ACHEAOC3DAO
SCHEMBL30471741 0.77 TYR (0.46) IDO1ADRB2HTTTRPA1ALDH1A1
SCHEMBL8750387 0.77 TYR (0.46) IDO1ADRB2HTTTRPA1ALDH1A1
SCHEMBL12027408 0.77 IDO1 (0.46) IDO1TDO2ACHEAOC3DAO
SCHEMBL424538 0.77 IDO1 (0.46) IDO1TDO2ACHEAOC3HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122059820-A Method for synthesizing carboxylic acid compound by titanium catalysis 陕西师范大学 2026-05-19 — — CN disclosed
US-12528761-B2 Thyromimetics AUTOBAHN THERAPEUTICS, INC. (US) 2026-01-20 — — US disclosed
US-12466781-B2 Thyromimetics AUTOBAHN THERAPEUTICS, INC. (US) 2025-11-11 — — US disclosed
US-20240182489-A1 New 5,6,7,8-Tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one Derivatives as Sigma Ligands ACONDICIONAMIENTO TARRASENSE (ES) 2024-06-06 — — US disclosed
EP-4308574-A1 NEW 5,6,7,8-TETRAHYDROPYRIDO[4',3':4,5] THIENO[2,3-D]PYRIMIDIN-4(3H)-ONE DERIVATIVES AS SIGMA LIGANDS Acondicionamiento Tarrasense (ES) 2024-01-24 — — EP disclosed
US-20230242471-A1 THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. 2023-08-03 — — US disclosed
US-20230242473-A1 THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. 2023-08-03 — — US disclosed
US-11667606-B2 Thyromimetics AUTOBAHN THERAPEUTICS, INC. (US) 2023-06-06 — — US disclosed
US-11667606-B2 Thyromimetics AUTOBAHN THERAPEUTICS, INC. (US) 2023-06-06 — — US disclosed
US-11667606-B2 Thyromimetics AUTOBAHN THERAPEUTICS, INC. (US) 2023-06-06 — — US disclosed
EP-1751131-A1 MTP INHIBITING ARYL PIPERIDINES OR PIPERAZINES SUBSTITUTED WITH 5-MEMBERED HETEROCYCLES JANSSEN PHARMACEUTICA N.V. (BE) 2007-02-14 — — EP disclosed
US-20060148811-A1 Aralkyl-ketone piperazine derivatives and their uses as new antalgic or ataractic agent SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) 2006-07-06 — — US disclosed
WO-2005085226-A1 MTP INHIBITING ARYL PIPERIDINES OR PIPERAZINES SUBSTITUTED WITH 5-MEMBERED HETEROCYCLES JANSSEN PHARMACEUTICA N.V. (BE) 2005-09-15 — — WO disclosed
EP-0279281-B1 LIPOXYGENASE INHIBITING COMPOUNDS ABBOTT LABORATORIES (US) 1992-08-26 — — EP disclosed
US-4897422-A TREATMENT OF ASTHMA, RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS, ANTIINFLAMMATORY AGENTS ABBOTT LABORATORIES (US) 1990-01-30 — — US disclosed
EP-0279281-A2 Lipoxygenase inhibiting compounds ABBOTT LABORATORIES (US) 1988-08-24 — — EP disclosed
EP-0005318-B1 N-HETEROCYCLYL-4-PIPERIDINAMINES, METHODS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, INTERMEDIATES THEREFOR, AND METHOD FOR THE PREPARATION OF THE INTERMEDIATES JANSSEN PHARMACEUTICA N.V. (BE) 1982-01-06 — — EP disclosed
US-4219559-A N-Heterocyclyl-4-piperidinamines JANSSEN PHARMACEUTICA N.V. (BE) 1980-08-26 — — US disclosed
US-4019893-A Herbicidal method using 2-sulfinyl or 2-sulfonyl pyridine N-oxide derivatives UNIROYAL INC. (US) 1977-04-26 — — US disclosed
US-3960542-A Herbicidal 2-sulfinyl and 2-sulfonyl pyridine N-oxide derivatives UNIROYAL INC. (US) 1976-06-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148811-A1 Aralkyl-ketone piperazine derivatives and their uses as new antalgic or ataractic agent AAK1, KCNJ1, KHK IDO1 2347/4885TDO2 3494/4885ACHE 89/4885
US-11667606-B2 Thyromimetics TPO, TSHR, TTR IDO1 165/4885TDO2 279/4885ACHE 80/4885
US-20240182489-A1 New 5,6,7,8-Tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one Derivatives as Sigma Ligands SIGMAR1, OPRD1, TMEM97 IDO1 1898/4885TDO2 2025/4885ACHE 2750/4885
US-12466781-B2 Thyromimetics TPO, TSHR, CHRM1 IDO1 140/4885TDO2 106/4885ACHE 131/4885
US-20230242473-A1 THYROMIMETICS TPO, THOP1, THRB IDO1 621/4885TDO2 695/4885ACHE 50/4885
US-12528761-B2 Thyromimetics TSHR, THRB, TTR IDO1 232/4885TDO2 188/4885ACHE 508/4885
US-20230242471-A1 THYROMIMETICS TPO, THOP1, THRB IDO1 568/4885TDO2 652/4885ACHE 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.